SCHEMBL753002

SCHEMBL753002

Cc1n[c]cc(NC(=O)N2CCN(C)CC2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.43
ALDH1A1 P00352 3/20 0.43
HSD17B10 Q99714 2/20 0.43
GSK3B P49841 3/20 0.41
DYRK1A Q13627 3/20 0.41
WNT1 P04628 1/20 0.41
ABL1 P00519 2/20 0.40
TDP1 Q9NUW8 2/20 0.40
HRH4 Q9H3N8 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
MAPT P10636 4/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
POLB P06746 2/20 0.38
RIN1 Q13671 1/20 0.38
GAA P10253 1/20 0.36
HPGD P15428 1/20 0.36
CASP1 P29466 1/20 0.36
ATM Q13315 1/20 0.36
EPHX2 P34913 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL751783 0.85 ALDH1A1 (0.47) KDM4EALDH1A1HSD17B10GSK3BDYRK1A
SCHEMBL13621173 0.67 FAAH (0.52) KDM4EALDH1A1HSD17B10GSK3BDYRK1A
SCHEMBL27892281 0.66 HTR3A (0.46) KDM4EALDH1A1HRH4KMT2ASMN1; SMN2
SCHEMBL4301473 0.65 KDM4E (0.59) KDM4EALDH1A1MAPTSMN1; SMN2POLB
SCHEMBL178450 0.65 NPC1 (0.73) KDM4EALDH1A1ABL1TDP1MEN1
SCHEMBL24381877 0.65 TSHR (0.50) KDM4EALDH1A1GSK3BDYRK1AWNT1
SCHEMBL23110242 0.64 ROCK2 (0.47) KDM4EALDH1A1HSD17B10GSK3BDYRK1A
SCHEMBL13621144 0.64 KDM4E (0.67) KDM4EALDH1A1ABL1TDP1MAPT
SCHEMBL14046661 0.64 POLB (0.73) KDM4EALDH1A1HSD17B10TDP1MEN1
SCHEMBL4300084 0.63 KDM4E (0.93) KDM4EALDH1A1HSD17B10TDP1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2430013-B1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC (US) 2014-10-15 EP disclosed
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors AMGEN INC. (US) 2012-07-26 US disclosed
EP-2430013-A1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS Amgen, Inc (US) 2012-03-21 EP disclosed
WO-2010132598-A1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC. (US) 2010-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors PIK3CA, PIKFYVE, PIK3CD KDM4E 1665/4885ALDH1A1 4785/4885HSD17B10 1569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.